Results 181 to 190 of about 1,878,157 (376)

Prevalence, Phenotype, and Correlates of Avoidant/Restrictive Food Intake Disorder Symptoms in the Gulf Cooperation Council: An Underserved Region

open access: yesInternational Journal of Eating Disorders, EarlyView.
ABSTRACT Introduction Prevalence estimates and correlates of ARFID in non‐Western samples are lacking. This study aims to estimate the prevalence of ARFID symptoms, identify its phenotypes, and explore its correlates in a community sample from the Gulf Cooperation Council (GCC).
Bernou Melisse   +8 more
wiley   +1 more source

Longitudinal Effects of Residential Treatment for Eating Disorders: Symptom Trajectories and Predictors of Functional Outcomes

open access: yesInternational Journal of Eating Disorders, EarlyView.
ABSTRACT Objective Residential treatment for eating disorders addresses the gap between inpatient and outpatient care, but evidence for longer‐term and functional outcomes remains limited. The current study examined both clinical and functional outcomes from admission to a 6‐month follow‐up from Australia's first residential service for eating ...
Sinead Day   +10 more
wiley   +1 more source

Mirtazapine Is Associated With Shorter Hospital Stay in Pediatric Avoidant Restrictive Food Intake Disorder—A Retrospective Chart Review

open access: yesInternational Journal of Eating Disorders, EarlyView.
ABSTRACT Objective Avoidant restrictive food intake disorder (ARFID) is a relatively new diagnostic entity, and no medication has been approved. Recent data suggest that mirtazapine, a tetracyclic antidepressant, could improve outcomes in ARFID. We conducted a retrospective chart review to examine the effects of mirtazapine on ARFID treatment in youth.
Aman Chishti   +6 more
wiley   +1 more source

Serum Amino Acid Profiling in Children with Autistic Spectrum Disorder: Insights from a Single-Center Study in Southern Romania. [PDF]

open access: yesHealthcare (Basel), 2023
Anastasescu CM   +9 more
europepmc   +1 more source

Severity of effect considerations regarding the use of mutation as a toxicological endpoint for risk assessment: A report from the 8th International Workshop on Genotoxicity Testing (IWGT)

open access: yesEnvironmental and Molecular Mutagenesis, EarlyView.
Abstract Exposure levels without appreciable human health risk may be determined by dividing a point of departure on a dose–response curve (e.g., benchmark dose) by a composite adjustment factor (AF). An “effect severity” AF (ESAF) is employed in some regulatory contexts.
Barbara L. Parsons   +17 more
wiley   +1 more source

Hyperlexia in a 4-year-old boy with Autistic Spectrum Disorder [PDF]

open access: green, 2006
Keith Atkin, Marjorie Perlman Lorch
openalex   +1 more source

Home - About - Disclaimer - Privacy